exemestane
Sign in to saveExemestane, sold under the brand name Aromasin among others, is a medication used to treat breast cancer. It is a member of the class of antiestrogens known as aromatase inhibitors. Some breast cancers require estrogen to grow. Those cancers have estrogen receptors (ERs), and are called ER-positive. They may also be called estrogen-responsive, hormonally-responsive, or hormone-receptor-positive. Aromatase is an enzyme that synthesizes estrogen. Aromatase inhibitors block the synthesis of estrogen. This lowers the estrogen level, and slows the growth of cancers.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 461098446
- Drug.IUPAC_name
- 6-Methylideneandrosta-1,4-diene-3,17-dione
- Drug.image
- Exemestane.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 225
- Drug.image2
- Exemestano.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 225
- Drug.tradename
- Aromasin
- Drug.MedlinePlus
- a607006
- Drug.routes_of_administration
- By mouth
- Drug.class
- Aromatase inhibitor; Antiestrogen
- Drug.ATC_prefix
- L02
- Drug.ATC_suffix
- BG06
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx only
via Wikipedia infobox
Article
14 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Overdose
- Interactions
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Chemistry
- Society and culture
- Performance enhancement
- Research
- References
- External links
Exemestane, sold under the brand name Aromasin among others, is a medication used to treat breast cancer. It is a member of the class of antiestrogens known as aromatase inhibitors. Some breast cancers require estrogen to grow. Those cancers have estrogen receptors (ERs), and are called ER-positive. They may also be called estrogen-responsive, hormonally-responsive, or hormone-receptor-positive. Aromatase is an enzyme that synthesizes estrogen. Aromatase inhibitors block the synthesis of estrogen. This lowers the estrogen level, and slows the growth of cancers.
==Medical uses== Exemestane is indicated for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to it for completion of a total of five consecutive years of adjuvant hormonal therapy. US FDA approval was in October 1999.